Wanbangde Pharmaceutical Holding Group Co., Ltd.
002082.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.16 | -1.69 | -1.33 | -1.29 |
| FCF Yield | 0.81% | -5.12% | -7.52% | -2.80% |
| EV / EBITDA | 27.84 | 28.22 | 17.21 | 29.66 |
| Quality | ||||
| ROIC | 1.19% | 0.63% | 2.52% | 4.58% |
| Gross Margin | 41.31% | 40.45% | 52.27% | 48.24% |
| Cash Conversion Ratio | 2.66 | -2.77 | -3.22 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.86% | -7.22% | -49.29% | -51.28% |
| Free Cash Flow Growth | 115.77% | 50.45% | -59.58% | 37.54% |
| Safety | ||||
| Net Debt / EBITDA | 4.76 | 4.22 | 1.17 | -0.23 |
| Interest Coverage | 1.49 | 0.56 | 3.79 | 10.17 |
| Efficiency | ||||
| Inventory Turnover | 3.96 | 3.59 | 3.01 | 3.82 |
| Cash Conversion Cycle | 251.40 | 268.55 | 280.32 | 221.27 |